Liraglutide with Short-Term CSII Improves Type 2 Diabetes Remission and Beta-Cell Function.
Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function
Study Design
Population
The study population consisted of patients with type 2 diabetes.
Intervention
Liraglutide was administered in conjunction with short-term continuous subcutaneous insulin infusion (CSII).
Outcome
The primary outcomes measured were type 2 diabetes remission and beta-cell function.
Abstract
Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function in Newly-diagnosed Type 2 Diabetic Patients
NCT ID: NCT01790308
Status: UNKNOWN
Sponsor: Sun Yat-sen University
Phase: PHASE4
Start: 20…